Retinoic acid and steroids inhibit Epstein-Barr virus-induced nuclear antigen, DNA synthesis and lymphocyte transformation.
Retinoic acid, dexamethasone and prednisolone were evaluated for their effects on Epstein-Barr virus (EBV)-induced nuclear antigen (EBNA), DNA synthesis and transformation of human thymus-independent, B lymphocytes. It was found that continuous treatment of target cells with these agents completely inhibited EBV-induced transformation events. However, discontinuous treatment of the virus-infected cultures with these agents resulted in the recovery of DNA synthesis, and the appearance of EBNA and transformation. When the cells were treated with these agents 8 days after the virus infection, the inhibitors had no effect. These results show that only continuous treatment with these agents inhibited EBV-mediated transformation; these inhibitors had no effect once the EBNA and EBV-induced DNA synthesis were initiated in target lymphocytes.
D000956:Antigens, Viral / Q000276:immunology*; D001402:B-Lymphocytes / Q000187:drug effects / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002472:Cell Transformation, Viral / Q000187:drug effects*; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis*; D003907:Dexamethasone / Q000494:pharmacology; D019309:Epstein-Barr Virus Nuclear Antigens; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D011239:Prednisolone / Q000494:pharmacology; D013256:Steroids / Q000494:pharmacology*; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology*
D000956:Antigens, Viral; D019309:Epstein-Barr Virus Nuclear Antigens; D013256:Steroids; D014212:Tretinoin; D003907:Dexamethasone; D004247:DNA; D011239:Prednisolone